PARIS (Reuters) – Valneva fell on the stock market on Friday in mid-session after the announcement by the French laboratory of the exclusion of a large percentage of participants in clinical trials on the candidate vaccine against Lyme disease that it develops with the American pharmaceutical group Pfizer.
On the Paris Stock Exchange, Valneva shares fell 9.78% to 5.736 euros, the largest drop in the SBF120, which itself lost 0.63% around 12:30 p.m. GMT. Pfizer stock is also flagged lower in trading ahead of the open on Wall Street.
In a press release, the two groups explain that they want to exclude from clinical trials a significant sample of participants in the tests carried out in the United States.
“After being made aware of possible GCP violations, Pfizer conducted a thorough review of practices and data collection at clinical trial centers operated by this third-party company and applied standardized protective measures to determine the most appropriate course of action,” their statement read.
According to Valneva and Pfizer, the exclusion of the participants concerned is not linked to problems with the safety of the candidate vaccine and nor to any adverse effects that would have been reported.
For Portzamparc analysts, it is difficult at this stage to assess the financial impact of these disruptions on Valneva.
“The question that remains is whether regulators will be able to accept a dossier that only includes data from half of the originally intended participants,” they write.
(Report Sudip Kar-Gupta and Bhanvi Satija, French version Matthieu Protard and Claude Chendjou, edited by Kate Entringer)
©2023 Thomson Reuters, all rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.